SG11202104404XA - Erk inhibitors and uses thereof - Google Patents
Erk inhibitors and uses thereofInfo
- Publication number
- SG11202104404XA SG11202104404XA SG11202104404XA SG11202104404XA SG11202104404XA SG 11202104404X A SG11202104404X A SG 11202104404XA SG 11202104404X A SG11202104404X A SG 11202104404XA SG 11202104404X A SG11202104404X A SG 11202104404XA SG 11202104404X A SG11202104404X A SG 11202104404XA
- Authority
- SG
- Singapore
- Prior art keywords
- erk inhibitors
- erk
- inhibitors
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
- C12N9/1205—Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862768565P | 2018-11-16 | 2018-11-16 | |
US201962908965P | 2019-10-01 | 2019-10-01 | |
PCT/US2019/061750 WO2020102686A1 (en) | 2018-11-16 | 2019-11-15 | Erk inhibitors and uses thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11202104404XA true SG11202104404XA (en) | 2021-05-28 |
Family
ID=70730924
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11202104404XA SG11202104404XA (en) | 2018-11-16 | 2019-11-15 | Erk inhibitors and uses thereof |
Country Status (12)
Country | Link |
---|---|
US (1) | US20220002294A1 (he) |
EP (1) | EP3880677A4 (he) |
JP (1) | JP2022507514A (he) |
KR (1) | KR20210130701A (he) |
CN (1) | CN113423707A (he) |
AU (1) | AU2019381808A1 (he) |
BR (1) | BR112021009430A2 (he) |
CA (1) | CA3119988A1 (he) |
IL (1) | IL283106A (he) |
MX (1) | MX2021005171A (he) |
SG (1) | SG11202104404XA (he) |
WO (1) | WO2020102686A1 (he) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP4212531A1 (en) * | 2022-01-14 | 2023-07-19 | AGV Discovery | Azaindole derivatives and their use as erk kinase inhibitors |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20070002081A (ko) * | 2004-04-02 | 2007-01-04 | 버텍스 파마슈티칼스 인코포레이티드 | Rock 및 기타 단백질 키나아제의 억제제로서 유용한아자인돌 |
ZA200700751B (en) * | 2004-06-30 | 2008-08-27 | Vertex Pharma | Azalndoles useful as inhibitors of protein kinases |
WO2007002433A1 (en) * | 2005-06-22 | 2007-01-04 | Plexxikon, Inc. | Pyrrolo [2, 3-b] pyridine derivatives as protein kinase inhibitors |
DE102008031517A1 (de) * | 2008-07-03 | 2010-01-07 | Merck Patent Gmbh | Pyrrolopyridinyl-pyrimidin-2-yl-amin-derivate |
NZ590784A (en) * | 2008-07-23 | 2012-12-21 | Vertex Pharma | Pyrazolopyridine kinase inhibitors |
DE102009043260A1 (de) * | 2009-09-28 | 2011-04-28 | Merck Patent Gmbh | Pyridinyl-imidazolonderivate |
DE102009060174A1 (de) * | 2009-12-23 | 2011-06-30 | Merck Patent GmbH, 64293 | Pyrrolopyridinyl-pyrimidin-2-yl-amin-derivate |
WO2012094313A1 (en) * | 2011-01-04 | 2012-07-12 | Kinentia Biosciences Llc | Pyrazole derivatives as erk inhibitors |
WO2013052355A1 (en) * | 2011-10-03 | 2013-04-11 | Merck Sharp & Dohme Corp. | Azaindoles as janus kinase inhibitors |
BR112015007214A8 (pt) * | 2012-10-16 | 2018-02-06 | Hoffmann La Roche | composto, método para a inibição da atividade da quinase, método para o tratamento, composição, utilização de um composto e invenção |
WO2014109414A1 (ja) * | 2013-01-11 | 2014-07-17 | 富士フイルム株式会社 | 含窒素複素環化合物またはその塩 |
LT3052096T (lt) * | 2013-10-03 | 2018-04-10 | Kura Oncology, Inc. | Erk inhibitoriai ir jų panaudojimo būdai |
WO2016026078A1 (en) * | 2014-08-19 | 2016-02-25 | Changzhou Jiekai Pharmatech Co., Ltd. | Heterocyclic compounds as erk inhibitors |
KR20170103838A (ko) * | 2015-01-23 | 2017-09-13 | 컨플루언스 라이프 사이언시스, 인코포레이티드 | 염증 및 암의 치료를 위한 헤테로시클릭 itk 저해제 |
EP3170822A1 (en) * | 2015-11-18 | 2017-05-24 | AGV Discovery | Azaindole derivatives and their use as erk kinase inhibitors |
CN107973783B (zh) * | 2016-10-21 | 2024-09-06 | 正大天晴药业集团股份有限公司 | 作为erk抑制剂的苯胺嘧啶衍生物 |
CN108948002A (zh) * | 2017-05-19 | 2018-12-07 | 厦门大学 | 五元并六元氮杂芳环类化合物、其制备方法、药用组合物及其应用 |
-
2019
- 2019-11-15 AU AU2019381808A patent/AU2019381808A1/en active Pending
- 2019-11-15 SG SG11202104404XA patent/SG11202104404XA/en unknown
- 2019-11-15 MX MX2021005171A patent/MX2021005171A/es unknown
- 2019-11-15 CA CA3119988A patent/CA3119988A1/en active Pending
- 2019-11-15 EP EP19884483.9A patent/EP3880677A4/en not_active Withdrawn
- 2019-11-15 CN CN201980085273.1A patent/CN113423707A/zh active Pending
- 2019-11-15 US US17/294,225 patent/US20220002294A1/en active Pending
- 2019-11-15 WO PCT/US2019/061750 patent/WO2020102686A1/en unknown
- 2019-11-15 JP JP2021526509A patent/JP2022507514A/ja active Pending
- 2019-11-15 BR BR112021009430-0A patent/BR112021009430A2/pt not_active Application Discontinuation
- 2019-11-15 KR KR1020217018334A patent/KR20210130701A/ko active Search and Examination
-
2021
- 2021-05-11 IL IL283106A patent/IL283106A/he unknown
Also Published As
Publication number | Publication date |
---|---|
CN113423707A (zh) | 2021-09-21 |
EP3880677A4 (en) | 2022-06-22 |
MX2021005171A (es) | 2021-10-01 |
IL283106A (he) | 2021-06-30 |
EP3880677A1 (en) | 2021-09-22 |
JP2022507514A (ja) | 2022-01-18 |
BR112021009430A2 (pt) | 2021-08-17 |
CA3119988A1 (en) | 2020-05-22 |
WO2020102686A1 (en) | 2020-05-22 |
AU2019381808A1 (en) | 2021-05-27 |
US20220002294A1 (en) | 2022-01-06 |
KR20210130701A (ko) | 2021-11-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL282487A (he) | מעכבים מסוג tyk2 והשימוש בהם | |
IL271999A (he) | מעכבי tyk2 ושימושים בהם | |
IL289612A (he) | מעכבי hpk1 ושימושים בהם | |
IL283409A (he) | מעכבי tyk2 ושימושים בהם | |
IL282090A (he) | מעכבי tyk2 ושימושים בהם | |
GB201605126D0 (en) | Inhibitors and their uses | |
ZA202002172B (en) | Pde9 inhibitor and use thereof | |
IL270330B (he) | מדכאי ביטא-לקטמז ושימושים בהם | |
EP3471726A4 (en) | CXCR4 INHIBITORS AND USES THEREOF | |
EP3572400C0 (en) | EZH2 INHIBITOR AND ITS USE | |
LT3621694T (lt) | Lrrc33 inhibitoriai ir jų panaudojimas | |
IL282350A (he) | מעכבים ברנני-rgmc ושימוש בהם | |
IL272649A (he) | מעכבי ahr ושימושים בהם | |
IL263949A (he) | מעכבי משלים ושימושיהם | |
IL291217A (he) | מעכבי usp30 ושימושים שלהם | |
IL279276A (he) | מעכב erk ושימוש בו | |
ZA201905934B (en) | Dual magl and faah inhibitors | |
IL292198A (he) | מעכבים של tim-3 ושימושים שלהם | |
GB201820088D0 (en) | Opitical devices and methods | |
EP3585809A4 (en) | THIOLISOMERASE INHIBITORS AND USES THEREOF | |
IL283106A (he) | מעכבי erk ושימושים בהם | |
EP3704104A4 (en) | IRAK4 INHIBITORS AND THEIR USES | |
EP3463371A4 (en) | KU INHIBITORS AND THEIR USE | |
IL280408A (he) | מעכבי cdk ושימושים בהם | |
EP3892619A4 (en) | SELECTIVE PI3KO INHIBITOR AND USE THEREOF |